高生长性肠道病毒71型疫苗候选株的研制:可诱导交叉反应性中和抗体应答
研究通过Vero细胞多次传代和蚀斑筛选,适应获得高生长性肠道病毒71型(EV71)B5基因型病毒(HG-B5),在微载体细胞培养系统中滴度可达>10^8 TCID50/mL,纯化后经铝佐剂配制,家兔肌内免疫两剂后可诱导针对A、B5和C4三个基因型的交叉反应性中和抗体。
要点
- HG-B5候选株在微载体培养系统中滴度>10^8 TCID50/mL。
- 家兔肌内免疫两剂HG-B5疫苗后可诱导针对A、B5和C4基因型的交叉反应性中和抗体。
- 现有5个候选疫苗峰值滴度仅约10^7 TCID50/mL,且基因型与当前台湾及东南亚主要流行株B5不同。
核心结论
- 成功在Vero细胞中适应获得高生长性EV71病毒,家兔免疫后可诱导针对A、B5和C4三个基因型的广谱中和抗体滴度。
研究设计与样本
- 研究将EV71 B5基因型病毒在Vero细胞中经多次传代和蚀斑筛选获得高生长性适应株HG-B5,在微载体细胞培养系统中培养,纯化后与铝佐剂配制,家兔肌内免疫两剂后检测中和抗体。
主要发现
- HG-B5病毒在微载体细胞培养系统中滴度可达>10^8 TCID50/mL。
- 现有5个候选疫苗峰值病毒滴度仅约10^7 TCID50/mL。
- 家兔肌内免疫两剂HG-B5疫苗后可诱导针对A、B5和C4三个基因型的交叉反应性中和抗体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although Enterovirus 71 (EV71) has only one serotype based on serum neutralization tests using hyperimmune animal antisera, three major genogroups (A, B and C) including eleven genotypes (A, B1-B2, and C1-C5) can be well classified based on phylogenetic analysis. Since 1997, large-scale EV71 epidemics occurred cyclically with different genotypes in the Asia-Pacific region. Therefore, development of EV71 vaccines is a national priority in several Asian countries. Currently, five vaccine candidates have been evaluated in clinical trials in China (three C4 candidates), Singapore (one B2 candidate), and Taiwan (one B4 candidate). Overall, the peak viral titers of these 5 vaccine candidates could only reach about 107 TCID50/mL. Moreover, genotypes of these 5 candidates are different from the current predominant genotype B5 in Taiwan and South-Eastern Asia. We adapted a high-growth EV71 genotype B5 (HG-B5) virus after multiple passages and plaque selections in Vero cells and the HG-B5 virus could reach high titers (>108 TCID50/mL) in a microcarrier-based cell culture system. The viral particles were further purified and formulated with alum adjuvant. After two doses of intramuscular immunization in rabbits, the HG-B5 vaccine candidate could induce cross-reactive neutralizing antibodies against the three major EV71 genogroups. In conclusion, a high-growth EV71 virus was successfully adapted in Vero cells and could induce broad spectrum neutralizing antibody titers against three (A, B5, and C4) genotypes in rabbits.
引用
- Chia MY, Chung WY, Wang CH, et al. Development of a high-growth enterovirus 71 vaccine candidate inducing cross-reactive neutralizing antibody responses. Vaccine. 2018. PMID: 29398272. doi:10.1016/j.vaccine.2018.01.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。